[Role of pharmaceutical company pharmacist in provision of drug information for cancer chemotherapy].
Recently, oxaliplatin(L-OHP)and irinotecan hydrochloride hydrate(CPT-11)have gained recognition as key drugs in the treatment of advanced colorectal cancer. In this article, we describe the results of a survey of medical institutions by pharmacists working at a pharmaceutical company. First, questions from medical institutions on L-OHP and CPT-11 were totaled and analyzed. The results showed that most of these questions concerned safety, with many of these addressing side effects. Next, a questionnaire on FOLFOX and FOLFIRI regimens was administered to medical institutions. The results indicated that staff are interested in the safety and critical path of these regimens. These results suggest that a lot of medical institutions require more information from pharmaceutical companies. This indicates that pharmacists should do more to take the needs of medical institutions into account in providing improved customer support.
Koshida
Iori
I
Yakult Honsha Co., Ltd.
Kubota
Kenichi
K
Yamashita
Masaki
M
Katayanagi
Hideya
H
Noda
Kohei
K
Terada
Hakaru
H
Yoshioka
Shinichi
S
Sekine
Nobuyuki
N
Kameda
Toshikazu
T
Terada
Kiyoshi
K
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D004345:Drug Industry; D006801:Humans; D007564:Japan; D009369:Neoplasms / Q000188:drug therapy*; D010595:Pharmacists / Q000592:standards*; D012955:Societies, Medical; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents